Pancreatic cancer and liver metastases: state of the art
|
|
- Malcolm Allen
- 6 years ago
- Views:
Transcription
1 Updates Surg (2016) 68: DOI /s REVIEW ARTICLE Pancreatic cancer and liver metastases: state of the art Eugen Bellon 1 Florian Gebauer 1 Michael Tachezy 1 Jakob R. Izbicki 1 Maximilian Bockhorn 1 Received: 8 June 2016 / Accepted: 18 October 2016 / Published online: 10 November 2016 Italian Society of Surgery (SIC) 2016 Abstract Pancreatic cancer is still one of the most aggressive oncological diseases with a 5-year mortality rate below 10%. Surgery remains the only curative treatment; however, most patients present with late-stage disease deemed unresectable, either due to extensive local vascular involvement or the presence of distant metastasis. In the detection of hepatic metastases, the current standard is palliative chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or nab-paclitaxel with gemcitabine. Once hepatic metastases are diagnosed, the guidelines do not recommend resection of the primary tumor. Recent findings suggest that some patients with non-resectable diseases initially have survival rates as good as those with initially resectable disease when they are able to undergo surgical resection. Synchronous resection of both the primary tumour as well as the liver metastases may be beneficial and improves the outcome. Keywords Pancreatic adenocarcinoma Liver metastasis Palliative chemotherapy Synchronous resection Introduction Pancreatic ductal adenocarcinoma (PDAC) is often perceived as an incurable disease by both patients and their physicians. While the outcome of most solid tumors has improved over the last 20 years, the median survival for & Maximilian Bockhorn M.bockhorn@uke.de 1 Department of General, Visceral and Thoracic SurgeryUniversity Medical Center Hamburg-Eppendorf, Martinistrasse 52, Hamburg, Germany patients with PDAC has steadily remained less than 12 months, even with the best therapeutic regimens currently available. Despite the discouraging statistics, approximately 20% of all patients who undergo surgical resection for PDAC survive 5 years. In contrast to localized tumor stages, the overall survival (OS) of patients with metastatic disease (M1) is even worse [1 3]. Once distant metastases are diagnosed, the guidelines do not recommend resection of the primary tumor [4, 5]. In such palliative settings, therapeutic regimes, such as FOLFIRNOX or gemcitabine and nab-paclitaxel, have been established recently, showing increased OS with a median of 11 and 8.5 months, respectively, compared to 7 or 6.7 months with single agent gemcitabine [2]. The increasing safety of operations in the recent decades with mortality rates of \5% has led to an extension of localized approaches in pancreatic operations, partially combined with neoadjuvant treatments [6, 7]. As a result, macroscopically complete resection seems to be one of the most important prognostic factors, but the performance of additional vessel resections and/or multivisceral resections (MVRs) must be weighed carefully against the increased morbidity and mortality of these procedures [8 11]. Not only locally advanced PDACs are operatively treated; indeed, small studies and case reports have described select patients with hepatic metastases undergoing curative resections of the pancreas and the hepatic metastases [12 14]. A decision for an intentional resection in a patient with PDAC metastatic to the liver has been made on a highly individual basis and is multifactorial, including the patient s wishes, age, clinical status, local resectability, and the individual risk of complications. In this subset of patients, synchronous resection of both the primary tumor, as well as the liver metastases may be beneficial and improve the outcome.
2 248 Updates Surg (2016) 68: Palliative chemotherapy Gemcitabine in a conventional dosage (1000 mg/m 2 in a 30-min infusion) is standard for the treatment of locally advanced and/or metastastic pancreatic carcinoma. The 1-year survival rate is 18 20% [15]. There is only a grade B recommendation for gemcitabin, as two more effective treatments exist for defined patient groups, namely, folfirinox and a combination of gemcitabine with nab-paclitaxel. As an alternative to gemcitabine monotherapy, combination therapy with gemcitabine and the EGF-receptor tyrosine kinase inhibitor erlotinib can be used for patients with metastatic pancreatic carcinoma [16]. A combination of 5-FU/folinic acid, irinotecan, and oxaliplatin (the folfrinox protocol) can be used in patients with metastatic pancreatic carcinoma who have a favorable risk profile (ECOG status 0 1, bilirubin value \1.5 times the upper limit of normal, age up to 75 years). This protocol significantly prolongs the overall survival compared to gemcitabine [median survival 11.1 versus 6.8 months, p \ , hazard ratio (HR) 0.57] [2]. It likewise prolongs progression-free survival from 3.3 to 6.4 months and has a higher response rate than gemcitabine (31.6%, compared to 9.4%). It is, however, also more toxic (grade III/IV neutropenia, 45.7 versus 18.7%; febrile neutropenia, 5.4 versus 0.6%; grade III/IV diarrhea, 12.7 versus 1.2%). Gemcitabine combined with nab-paclitaxel (G? nab-p) is a further new treatment option for metastatic pancreatic carcinoma that was just approved for use in the European Union. In a phase III trial, this combination was found to improve median progression-free survival (PFS), overall survival (OS), and tumor response rates significantly in comparison with gemcitabine alone [PFS: G? nab-p: 5.5 months versus G: 37 months, HR = 0.69 (95% CI ); p \ 0.001; OS: G? nab-p: 8.5 months; G: 6.7 months, HR = 0.72 (95% CI ); p \ 0.001; response rate (RR) G? nab-p: 23%, G: 7%] [17]. Grade III/IV hematotoxicity, fatigue, neuropathy, and diarrhea were all more common in the combination group. Combinations of gemcitabine with oxaliplatin, cisplatin, or capecitabin should not be used as the standard first-line therapy for metastatic or locally advanced pancreatic carcinoma, as a significant prolongation of survival with such combinations in comparison with gemcitabine monotherapy has been documented only in meta-analyses [15, 18](Table1). Synchrounous resection of metastatic pancreatic cancer Currently, complete operative resection of localized PDAC remains the only available treatment option with curative intent in this aggressive disease. Because the majority of patients are diagnosed after the disease has become unresectable, curatively aimed resection is performed in only a small subset of patients [19]. Nonetheless, as shown in the literature [20], macroscopically tumor-free resection is a powerful tool to prolong the overall survival of patients with PDAC. In consideration of the increasing safety of liver and pancreatic resections, the impact on OS, symptom control, and quality of life of synchronous resections in selected cases of oligometastatic disease is being revisited. In other malignancies, such as colorectal cancer, sarcoma, and even gastric cancer, evidence is increasing that metastasectomies can increase survival of selected patients if performed safely and in appropriate candidates [13, 21, 22]. Published data dealing with this issue are rare and restricted to small case series and a number of case reports. The resection of the primary tumor and synchronous liver metastases is not recommended under current national and international guidelines for the treatment of PDAC, and therefore, this particular treatment is performed only in highly selected patients [4, 5]. Eight reports, including C9 patients, found median OS between 5.9 and 11.4 months after resection [13, 14, 23 28]. Five of these studies present comparative groups of patients with M1 disease (TNM classification) without resection of the primary PDAC, 4 of them with less OS compared to the resection group (median OS months versus months, respectively, Table 2 [14, 23, 24, 26, 28] In accordance with these studies, the data in an analysis of patients from six European pancreas centers suggested a Table 1 Recent randomized and controlled trials on combination chemotherapy showing a survival advantage over gemcitabine monotherapy in the palliative setting References N Treatment regimen Progression-free survival Overall survival 1-year survival rate Moore [3] 569 Gemcitabine? erlotinib versus gemcitabin 3.75 versus 3.55 months (HR 0.77, p = 0.004) Conroy [2] 342 Folfirinox versus gemcitabin 6.4 versus 3.3 months (HR 0.47, p \ 0.001) Von Hoff [17] * p-value less than Gemcitabine? nab-paclitaxel versus gemcitabin 5.5 versus 3.7 months (HR 0.69, p \ 0.001) 6.24 versus 5.91 months (HR 0.82, p = 0.038)* 11.1 versus 6.8 months (HR 0.57, p \ 0.001) 8.5 versus 6.7 months (HR 0.72, p \ 0.001) 23 versus 17% (p = 0.023)* 48 versus 21% (p \ 0.001) 35 versus 22% (p \ 0.001)
3 Updates Surg (2016) 68: significant survival benefit with acceptable morbidity and mortality for patients receiving a combined liver and pancreas resection compared with patients with liver metastases who did not undergo resection of the primary PDAC (14.5 versus 7.5 months, p \ 0.001) [29] Despite the expected greater perioperative morbidity, mortality was not increased in the resection group. Only a small percentage of patients received neoadjuvant therapy and primarily in the resected patient group. There was no impact of neoadjuvant therapy on OS. The primary adjuvant therapy after the operation was gemcitabine-based and did not differ between the two groups; indeed, during the timespan of this study, gemcitabine was the standard of care in both the adjuvant and palliative setting [30, 31]. Only a few patients were given FOLFIRINOX as the firstor second-line treatment due to the timeframe of the study, [15 years before publication of the FOLFIRINOX trial [2]. The median OS of patients after resection of the primary PDAC and synchronous liver metastases tended to be greater compared with patients in the non-resection group [14.5 months, 95% confidence interval (CI) months and median 7.5 months, 95% CI months, p \ 0.001]. The 5-year survival was 0% in the non-resection group, while 4 of 69 evaluable patients (5.8%) after combined resection were still alive after 5 years. Despite the collaboration of eight high-volume centers in Europe, the total sample size was rather small over this 20-year interval (n = 69); therefore, the subgroup analyses of either head or body/tail resections resulted in even smaller group sizes, limiting the interpretation and conclusions. While the benefit in OS appears to be in the group of PDACs to the right of the portal axis, no benefit was apparent with left-sided PDACs, especially when the increase in morbidity is taken into consideration. In general, localized pancreatic body/tail PDACs have a better OS than PDACs in the head, but this effect is not present in stage IV PDACs. The limited prognosis is generally considered to be driven by distant metastasis and not by the site of the primary tumor [32] (Fig. 1). Table 2 Survival data from studies with combined synchronous hepatic and pancreatic resections and a palliative bypass group (patients n C 9) No resection Resection Significance Median (n) Median (n) (p) Takada et al. [26] [min max] [min max] 11 N/A Shrikhande et al. [23] [95% CI] [95% CI] Gleisner et al. [28] 5.6 N/A N/A Yamada et al [24] 6.8 N/A N/A 11 NS 4.1 N/A 26 Dünschede et al. [14] [IQR] [IQR] 9 N/A CI confidence interval, N/A not applicable, NS non significant, IQR interquartile range Fig. 1 Kaplan Meier survival curves showing the overall survival of the resection and non-resection groups in the complete cohort (left), pancreatic head tumors (middle), and pancreatic body and tail tumors (right)
4 250 Updates Surg (2016) 68: Conclusion As recently promoted by Conroy and colleagues [2], an intensified chemotherapeutic regimen (FOLFIRINOX) in the palliative setting (including peritoneal, pulmonary, and hepatic metastases as well as local disease) showed promising results with an observed OS of 11.1 months, but this regimen is toxic and results in greatly increased rates of grades III and IV toxicity compared with gemcitabine monotherapy. Therefore, this chemotherapeutic option may be appropriate only for a small subset of patients, especially when taking into consideration that even the adjuvant standard regimen with gemcitabine is not always well tolerated and cannot be completed in a substantial percentage of patients. Despite increased toxicity rates, the overall quality of life of patients receiving FOLFIRINOX as palliative therapy is increased compared to gemcitabine mono- therapy, likely due to an increase in the time to deterioration, as assumed by the authors. This aspect further highlights the need for quality-of-life assessments when such palliative trials are performed. One might suggest that the outcome of patients in the resectable group could be further improved by combining both treatment approaches in a perioperative neoadjuvant setting, either with FOLFIXRINOX or gemcitabine/nabpaclitaxel therapy. The crucial question is, which patients might benefit from such an approach? Should only patients with a stable disease or a disease that appeared to regress after neoadjuvant therapy be offered aggressive combined resection, or should resection be performed in chemonaive patients with a small tumor burden, considering the number of metastases correlates with patient survival? Future prospective trials should compare the impact on OS, morbidity, and quality of life of systemic chemotherapy with FOLFIRINOX or combined resections in the case of a preoperative therapeutic response. Compliance with ethical standards Conflict of interest The authors declare that they have no conflict of interest. Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Research involving human participants and/or animals This article does not contain any studies with human participants or animals performed by any of the authors. Informed consent Informed consent was obtained from all individual participants included in the study. References 1. Heinemann V, Haas M, Boeck S (2012) Systemic treatment of advanced pancreatic cancer. Cancer Treat Rev 38: Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: Seufferlein T, Porzner M, Becker T, Budach V, Ceyhan G, Esposito I et al (2013) S3-guideline exocrine pancreatic cancer. Z Gastroenterol 51: Tempero MA, Malafa MP, Behrman SW, Benson AB 3rd, Casper ES, Chiorean EG et al (2014) Pancreatic adenocarcinoma, version : featured updates to the NCCN guidelines. J Natl Compr Canc Netw 12: Tachezy M, Gebauer F, Petersen C, Arnold D, Trepel M, Wegscheider K et al (2014) Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA a randomized multicenter phase III study (NCT , DRKS , ISRCTN ). BMC Cancer 14: Bockhorn M, Uzunoglu FG, Adham M, Imrie C, Milicevic M, Sandberg AA et al (2014) Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 155: Tachezy M, Bockhorn M, Gebauer F, Vashist YK, Kaifi JT, Izbicki JR (2011) Bypass surgery versus intentionally incomplete resection in palliation of pancreatic cancer: is resection the lesser evil? J Gastrointest Surg 15: Burdelski CM, Reeh M, Bogoevski D, Gebauer F, Tachezy M, Vashist YK et al (2011) Multivisceral resections in pancreatic cancer: identification of risk factors. World J Surg 35: Bockhorn M, Burdelski C, Bogoevski D, Sgourakis G, Yekebas EF, Izbicki JR (2011) Arterial en bloc resection for pancreatic carcinoma. Br J Surg 98: Bockhorn M, Cataldegirmen G, Kutup A, Marx A, Burdelski C, Vashist JK et al (2009) Crossing the Rubicon: when pancreatic resection with curative intent ends in an R2 status. Impact of desmoplastic pseudo-pancreatitis and anatomical site of irresectability. Ann Surg Oncol 16: Michalski CW, Erkan M, Huser N, Muller MW, Hartel M, Friess H et al (2008) Resection of primary pancreatic cancer and liver metastasis: a systematic review. Dig Surg 25: Klein F, Puhl G, Guckelberger O, Pelzer U, Pullankavumkal JR, Guel S et al (2012) The impact of simultaneous liver resection for occult liver metastases of pancreatic adenocarcinoma. Gastroenterol Res Pract 2012: Dunschede F, Will L, von Langsdorf C, Mohler M, Galle PR, Otto G et al (2010) Treatment of metachronous and simultaneous liver metastases of pancreatic cancer. Eur Surg Res 44: Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P (2007) Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 25: Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:
5 Updates Surg (2016) 68: Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369: Hu J, Zhao G, Wang HX, et al (2011) A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma. Journal of Hematology and Oncology 19. Konstantinidis IT, Warshaw AL, Allen JN, Blaszkowsky LS, Castillo CF, Deshpande V et al (2013) Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a true R0 resection? Ann Surg 257: Hartwig W, Vollmer CM, Fingerhut A, Yeo CJ, Neoptolemos JP, Adham M et al (2014) Extended pancreatectomy in pancreatic ductal adenocarcinoma: definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS). Surgery 156: Stein A, Bokemeyer C (2014) How to select the optimal treatment for first line metastatic colorectal cancer. World J Gastroenterol 20( ): Pawlik TM, Vauthey JN, Abdalla EK, Pollock RE, Ellis LM, Curley SA (2006) Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. Arch Surg 141: Shrikhande SV, Kleeff J, Reiser C, Weitz J, Hinz U, Esposito I et al (2007) Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol 14: Yamada S, Fujii T, Sugimoto H, Kanazumi N, Kasuya H, Nomoto S et al (2009) Pancreatic cancer with distant metastases: a contraindication for radical surgery? Hepatogastroenterology 56: Klempnauer J, Ridder GJ, Bektas H, Pichlmayr R (1996) Extended resections of ductal pancreatic cancer impact on operative risk and prognosis. Oncology 53: Takada T, Yasuda H, Amano H, Yoshida M, Uchida T (1997) Simultaneous hepatic resection with pancreato-duodenectomy for metastatic pancreatic head carcinoma: does it improve survival? Hepatogastroenterology 44: Seelig SK, Burkert B, Chromik AM, Tannapfel A, Uhl W, Seelig MH (2010) Pancreatic resections for advanced M1-pancreatic carcinoma: the value of synchronous metastasectomy. HPB Surg 2010: Gleisner AL, Assumpcao L, Cameron JL, Wolfgang CL, Choti MA, Herman JM et al (2007) Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified? Cancer 110: Tachezy M, Gebauer F, Janot M, Uhl W, Zerbi A, Montorsi M, Perinel J, Adham M, Dervenis C, Agalianos C, Malleo G, Maggino L, Stein A, Izbicki JR, Bockhorn M (2016) Synchronous resections of hepatic oligometastatic pancreatic cancer: disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis. Surgery 2: Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K et al (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297: Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D et al (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304: Lau MK, Davila JA, Shaib YH (2010) Incidence and survival of pancreatic head and body and tail cancers: a population-based study in the United States. Pancreas 39:
Reference No: Author(s) 12/05/16. Approval date: committee. June Operational Date: Review:
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Pancreatic Adenocarcinoma Dr Colin Purcell, Consultant Medical Oncologist & on behalf of the GI Oncologists Group, Cancer
More informationIntended for use by Clinicians and Health Care Providers involved in the Management or Referral of adult patients with pancreatic
Intended for use by Clinicians and Health Care Providers involved in the Management or Referral of adult patients with pancreatic cancer Section AA Cancer Centre Referrals In the absence of metastatic
More informationMetastasectomy of pancreatic and periampullary adenocarcinoma to solid organ: The current evidence
JBUON 2018; 23(6): 1648-1654 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Metastasectomy of pancreatic and periampullary adenocarcinoma to solid
More informationCase 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?
Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old
More informationAdjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009
HIGHLIGHT ARTICLE - Slide Show Adjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009 Muhammad Wasif Saif
More informationClinical Study Pancreatic Resections for Advanced M1-Pancreatic Carcinoma: The Value of Synchronous Metastasectomy
HPB Surgery Volume 2010, Article ID 579672, 6 pages doi:10.1155/2010/579672 Clinical Study Pancreatic Resections for Advanced M1-Pancreatic Carcinoma: The Value of Synchronous Metastasectomy S. K. Seelig,
More informationPancreatic Ca Update
Pancreatic Ca Update Caio Max S. Rocha Lima, M.D. M. Robert Cooper Professor in Medical Oncology Co-leader GI Oncology and Co-leader Phase I Program Wake Forest School of Medicine E-mail:crochali@wakehealth.edu
More informationShimura et al. Surgical Case Reports (2017) 3:132 DOI /s
Shimura et al. Surgical Case Reports (2017) 3:132 DOI 10.1186/s40792-017-0409-9 CASE REPORT Open Access A long-term survival case treated with conversion surgery following chemotherapy after diagnostic
More informationIntroduction. Se Joon Lee, MD 2 Dong Ki Lee, MD 2 Dong Sup Yoon, MD 3
pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2015;47(2):266-273 Original Article http://dx.doi.org/10.4143/crt.2013.158 Open Access Gemcitabine Combined with Capecitabine Compared to Gemcitabine
More informationReference No: Author(s) Approval date: 12/05/16. Committee. June Operational Date: Review:
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Biliary Tract Cancer (BTC) Dr Colin Purcell, Consultant Medical Oncologist on behalf of the GI Oncologists Group, Cancer
More informationSurgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study
Original article Annals of Gastroenterology (2013) 26, 346-352 Surgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study Subhankar Chakraborty
More informationADENOCARCINOMA OF THE PANCREAS
ADENOCARCINOMA OF THE PANCREAS Effective Date: November 2017 Copyright (2017) Alberta Health Services This material is protected by Canadian and other international copyright laws. All rights reserved.
More informationPancreatic Adenocarcinoma
Pancreatic Adenocarcinoma AProf Lara Lipton 28 April 2018 Percentage alive 5 years after diagnosis for men and women Epidemiology 6% of cancer related deaths worldwide 4 th highest cause of cancer death
More informationChanging paradigm in pancreatic cancer: from adjuvant to neoadjuvant chemoradiation
Original Article Changing paradigm in pancreatic cancer: from adjuvant to neoadjuvant chemoradiation Justin D. Anderson 1, Wen Wan 2, Brian J. Kaplan 3, Jennifer Myers 4, Emma C. Fields 1 1 Department
More informationResults of Adjuvant Surgery after Combination Chemotherapy for Pancreatic Carcinoma with Multiple Liver Metastases
ORIGINAL ARTICLE Results of Adjuvant Surgery after Combination Chemotherapy for Pancreatic Carcinoma with Multiple Liver Metastases Shinichi Ikuta 1, Takashi Sonoda 2, Tsukasa Aihara 1, Tomojiro Ono 1,
More informationOverview. What s New in the Treatment of Pancreatic Cancer? Lots! Steven J. Cohen, M.D. Fox Chase Cancer Center September 17, 2013
What s New in the Treatment of Pancreatic Cancer? Lots! Steven J. Cohen, M.D. Fox Chase Cancer Center September 17, 2013 Overview Staging and Workup Resectable Disease Surgery Adjuvant therapy Locally
More informationRe-Resection of isolated recurrent Pancreatic Cancer. Thilo Hackert May 31, 2013
Re-Resection of isolated recurrent Pancreatic Cancer Thilo Hackert May 31, 2013 PDAC Recurrence Surgical Topics follow-up after PDAC resection type of recurrence management - local - solitary metastasis
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationCáncer de Páncreas: Optimización del tratamiento sistémico
Cáncer de Páncreas: Optimización del tratamiento sistémico Alfredo Carrato Hospital Universitario Ramón y Cajal, Madrid 16 de Mayo de 2015 Pancreatic cancer screening There is a latency period of about
More informationWhat Is The Optimal Adjuvant Therapy in Pancreatic Adenoca: Intensified Chemotherapy March 28 th, 2015
What Is The Optimal Adjuvant Therapy in Pancreatic Adenoca: Intensified Chemotherapy March 28 th, 2015 Eileen M. O Reilly, M.D. Associate Director David M. Rubenstein Center Pancreatic Cancer Research
More information2. Cost-Effectiveness Analysis
Cost effectiveness of nab-paclitaxel (Abraxane ) + gemcitabine as a combination therapy for metastatic pancreatic cancer in Ireland, eligible for reimbursement as a hospital only product. The National
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationPancreatic Cancer - Resected
Pancreatic Cancer - Resected GI Practice Guideline Dr. Michael Sanatani, MD. FRCPC Dr. Francisco Perera, MD, FRCPC Dr. Brian Dingle, MD, FRCPC Approval Date: October 4, 2007 This guideline is a statement
More informationPancreas Cancer Update Systemic Treatments
Pancreas Cancer Update Systemic Treatments Carlos R Becerra. Baylor University Medical Center Stage Distribution for Pancreas Cancer in the US (24-21) 1 9 8 7 Axis Title 6 5 4 53 3 28 2 1 9 11 Localized
More informationMANAGEMENT OF COLORECTAL METASTASES. Robert Warren, MD. The Postgraduate Course in General Surgery March 22, /22/2011
MANAGEMENT OF COLORECTAL METASTASES Robert Warren, MD The Postgraduate Course in General Surgery March 22, 2011 Local Systemic LIVER TUMORS:THERAPEUTIC OPTIONS Hepatoma Cholangio. Neuroendo. Colorectal
More informationPANCREATECTOMY WITH MESENTERIC AND PORTAL VEIN RESECTION FOR BORDERLINE RESECTABLE PANCREATIC CANCER: MULTICENTER STUDY
PROPOSAL: PANCREATECTOMY WITH MESENTERIC AND PORTAL VEIN RESECTION FOR BORDERLINE RESECTABLE PANCREATIC CANCER: MULTICENTER STUDY Pancreatic carcinoma represents the fourth-leading cause of cancer-related
More informationPancreatic Cancer Where are we?
Pancreatic Cancer Treatment Approaches & Options Pancreatic Cancer Action Network OUMC 9/22/2016 Russell G. Postier, MD Pancreatic Cancer Where are we? Estimated 2016 data 3% of cancer cases 7% of cancer
More informationPatient and caregiver awareness of pancreatic cancer treatments and clinical trials
Original Article Patient and caregiver awareness of pancreatic cancer treatments and clinical trials Anitra Engebretson 1, Lynn Matrisian 2, Cara Thompson 3 1 Pancreatic Cancer Action Network, Manhattan
More informationAdjuvant therapy in pancreatic cancer Monotherapy for whom? JL VAN LAETHEM, MD,PhD
Adjuvant therapy in pancreatic cancer Monotherapy for whom? JL VAN LAETHEM, MD,PhD Efficacy Parameters in adjuvant monochemotherapy Randomized studies in resectable PDAC Regimen DFS HR (p) OS HR (p) 5-yr-OS
More informationTough to treat tumors in elderly. how far can we go? Jean-Luc Raoul Institut Paoli-Calmettes Marseille France
Tough to treat tumors in elderly Pancreatic cancer: how far can we go? Jean-Luc Raoul Institut Paoli-Calmettes Marseille France Top 5 causes of cancer death / age Cancer Statistics in the USA 2008, CA
More informationGI Tumor Board 3/8/2018. Case #1 IDEA. Case #1 Question #1 What is the next step in management?
GI Tumor Board Edward Kim George Poultsides Naseem Esteghamat Kenzo Hirose May Cho Alan Venook Arta Monjazeb Margaret Tempero George Fisher Andrew Ko Daniel Chang Thomas Semrad Sisi Haraldsdottir Case
More informationPhase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma
Original Article Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma Werner Scheithauer 1, Gabriela Kornek 1, Gerald Prager 1, Nadja Stranzl 1, Friedrich
More informationThe role of hepatic artery lymph node in pancreatic adenocarcinoma: prognostic factor or a selection criterion for surgery
DOI:10.1111/hpb.12306 HPB ORIGINAL ARTICLE The role of hepatic artery lymph node in pancreatic adenocarcinoma: prognostic factor or a selection criterion for surgery Prejesh Philips, Erik Dunki-Jacobs,
More informationLA CHEMIOTERAPIA DI I LINEA
DECIDERE LA CHEMIOTERAPIA ADIUVANTE E DELLA MALATTIA METASTATICA LA CHEMIOTERAPIA DI I LINEA Michele Reni Department of Medical Oncology IRCCS Ospedale San Raffaele Milan, Italy 1930 1940 1950 1960 1970
More informationGemcitabine (1000mg/m 2 ) Monotherapy - 28 day
Gemcitabine (1000mg/m 2 ) Monotherapy - 28 day INDICATIONS FOR USE: Regimen INDICATION ICD10 Code Adjuvant chemotherapy for pancreatic adenocarcinoma C25 00284a Treatment of elderly patients or patients
More informationTrends in Neoadjuvant Approaches in Pancreatic Cancer
1070 Trends in Neoadjuvant Approaches in Pancreatic Cancer Lingling Du, MD, and Andrea Wang-Gillam, MD, PhD Abstract Pancreatic cancer (PDAC) is an aggressive tumor type associated with development of
More informationControversies in the Adjuvant Treatment of Pancreatic Adenocarcinoma
EDITORIAL Controversies in the Adjuvant Treatment of Pancreatic Adenocarcinoma Muhammad Wasif Saif Yale University School of Medicine. New Haven, CT, USA Summary There is no universally accepted standard
More informationThe 2010 Gastrointestinal Cancers Symposium Oral Abstract Session: Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract
The 2010 Gastrointestinal Cancers Symposium : Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract Abstract #131: Phase I study of MK 0646 (dalotuzumab), a humanized monoclonal antibody against
More informationCisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. Valle J et al. N Engl J Med 2010;362(14):
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer Valle J et al. N Engl J Med 2010;362(14):1273-81. Introduction > Biliary tract cancers (BTC: cholangiocarcinoma, gall bladder cancer,
More informationPancreatic Cancer and Radiation Therapy
Pancreatic Cancer and Radiation Therapy Why? Is there a role for local therapy with radiation in a disease with such a high rate of distant metastases? When? Resectable Disease Is there a role for post-op
More informationQuality of Life After Adjuvant Intra-Arterial Chemotherapy and Radiotherapy Versus Surgery Alone in Resectable Pancreatic and Periampullary Cancer
Quality of Life After Adjuvant Intra-Arterial Chemotherapy and Radiotherapy Versus Surgery Alone in Resectable Pancreatic and Periampullary Cancer A Prospective Randomized Controlled Study Marjolein J.
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationChemoradiation in patients with isolated recurrent pancreatic cancer - therapeutical efficacy and probability of re-resection
Habermehl et al. Radiation Oncology 2013, 8:27 RESEARCH Open Access Chemoradiation in patients with isolated recurrent pancreatic cancer - therapeutical efficacy and probability of re-resection Daniel
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More informationTrattamento chirurgico delle lesioni epatiche secondarie difficili. Adelmo Antonucci Chirurgia Oncologica e Epato-bilio-pancreatica
Trattamento chirurgico delle lesioni epatiche secondarie difficili Adelmo Antonucci Chirurgia Oncologica e Epato-bilio-pancreatica What does it mean difficult lesions? Diagnosis Treatment Small size Unfit
More informationSurgical Management of Pancreatic Cancer
I Congresso de Oncologia D Or July 5-6, 2013 Surgical Management of Pancreatic Cancer Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University School of Medicine, Baltimore, MD Estimated
More informationThe Role of Adjuvant Chemotherapy for Patients with Resected Pancreatic Cancer: Systematic Review of Randomized Controlled Trials and Meta-Analysis
Oncology Clinical Study Oncology 2007;72:314 321 DOI: 10.1159/000113054 Received: August 13, 2007 Accepted: August 13, 2007 Published online: January 14, 2008 The Role of Adjuvant Chemotherapy for Patients
More informationHow to deal with synchronous primary and liver metastases
How to deal with synchronous primary and liver metastases Luis Sabater Ortí MD, PhD Associate Professor University of Valencia European Board Surgical Qualification HBP (EBSQ-HPB) Department of Surgery.
More informationPancreatic Cancer in adults:
National Institute for Health and Care Excellence Version 1.0 Pancreatic Cancer in adults: diagnosis and management Appendix K 31 July 2017 Draft for Consultation Developed by the National Guideline Alliance,
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationTreatment of Colorectal Liver Metastases State of the Art
Treatment of Colorectal Liver Metastases State of the Art Eddie K. Abdalla, MD, FACS Professor and Chairman of Surgery Chief of Hepatobiliary Surgery Hilton Metropolitan Palace Hotel Beirut 16 November,
More informationTechnology appraisal guidance Published: 6 September 2017 nice.org.uk/guidance/ta476
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer Technology appraisal guidance Published: 6 September 2017 nice.org.uk/guidance/ta476 NICE 2018. All
More informationNeoadjuvant radiotherapy for pancreatic cancer: rationale and outcomes
Review Article Neoadjuvant radiotherapy for pancreatic cancer: rationale and outcomes Rohan Deraniyagala, Emily D. Tanzler The University of Florida College of Medicine Department of Radiation Oncology,
More informationABSTRACT ORIGINAL RESEARCH
Adv Ther (2018) 35:1564 1577 https://doi.org/10.1007/s12325-018-0784-z ORIGINAL RESEARCH Comparative Effectiveness of nab-paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective
More informationGemcitabine and Capecitabine for Advanced Adenocarcinoma of the Pancreas
Gemcitabine and Capecitabine for Advanced Adenocarcinoma of the Pancreas Robert D. Levin, MD Abstract Background: Chemotherapy for advanced adenocarcinoma of the pancreas may have severe toxicities including
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
More informationCholangiocarcinoma. GI Practice Guideline. Michael Sanatani, MD, FRCPC (Medical Oncologist) Barbara Fisher, MD, FRCPC (Radiation Oncologist)
Cholangiocarcinoma GI Practice Guideline Michael Sanatani, MD, FRCPC (Medical Oncologist) Barbara Fisher, MD, FRCPC (Radiation Oncologist) Approval Date: October 2006 This guideline is a statement of consensus
More informationThe prevalence of pancreatic adenocarcinoma (PDAC) continues
FEATURE Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer Cristina R. Ferrone, MD, Giovanni Marchegiani, MD,
More informationWhen to Integrate Surgery for Metatstatic Urothelial Cancers
When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male
More informationLong term survival study of de-novo metastatic breast cancers with or without primary tumor resection
Long term survival study of de-novo metastatic breast cancers with or without primary tumor resection Dr. Michael Co Division of Breast Surgery Queen Mary Hospital The University of Hong Kong Conflicts
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Nab-Paclitaxel (Abraxane) for Pancreatic Cancer September 23, 2014
pan-canadian Oncology Drug Review Final Clinical Guidance Report Nab-Paclitaxel (Abraxane) for Pancreatic Cancer September 23, 2014 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationState of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan
State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan Consultant GI Medical Oncologist National Cancer Centre Singapore Clinician Scientist, Genome Institute of Singapore OS (%) Overall survival
More informationThe Impact of Postoperative Complications on the Administration of Adjuvant Therapy Following Pancreaticoduodenectomy for Adenocarcinoma
Ann Surg Oncol (2014) 21:2873 2881 DOI 10.1245/s10434-014-3722-6 ORIGINAL ARTICLE PANCREATIC TUMORS The Impact of Postoperative Complications on the Administration of Adjuvant Therapy Following Pancreaticoduodenectomy
More informationLong-term survival with repeat resection for lung oligometastasis from pancreatic ductal adenocarcinoma: a case report
Matsuki et al. Surgical Case Reports (2018) 4:26 https://doi.org/10.1186/s40792-018-0435-2 CASE REPORT Open Access Long-term survival with repeat resection for lung oligometastasis from pancreatic ductal
More informationPancreas Quizzes c. Both A and B a. Directly into the blood stream (not using ducts)
Pancreas Quizzes Quiz 1 1. The pancreas produces hormones. Which type of hormone producing organ is the pancreas? a. Endocrine b. Exocrine c. Both A and B d. Neither A or B 2. Endocrine indicates hormones
More informationOutcomes of adjuvant radiotherapy and lymph node resection in elderly patients with pancreatic cancer treated with surgery and chemotherapy
Original Article Outcomes of adjuvant radiotherapy and lymph node resection in elderly patients with pancreatic cancer treated with surgery and chemotherapy Jessica Frakes 1, Eric A. Mellon 1, Gregory
More informationIl paziente anziano con malattia oncologica avanzata: il tumore del colon-retto
Milano 05.10.2018 Il paziente anziano con malattia oncologica avanzata: il tumore del colon-retto Salvatore Corallo U.O.C. Oncologia Medica IRCCS Istituto Nazionale dei Tumori Milano CRC in elderly patients
More informationTowards an optimal treatment algorithm for metastatic pancreatic ductal adenocarcinoma (PDA)
REVIEW ARTICLE Towards an optimal treatment algorithm for metastatic pancreatic ductal adenocarcinoma (PDA) M. Uccello md,* M. Moschetta PhD md,* G. Mak md,* T. Alam BSc (Hons),* C. Murias Henriquez md,*
More informationAfternoon Session Cases
Afternoon Session Cases Case 1 19 year old woman Presented with abdominal pain to community hospital Mild incr WBC a14, 000, Hg normal, lipase 100 (normal to 75) US 5.2 x 3.7 x 4 cm mass in porta hepatis
More informationPromoting Innovative Practice
Promoting Innovative Practice Development of centralised care in advanced pancreatic cancer 1 Dr Olosula O Faluyi, Consultant in Medical Oncology and Dr Daniel H Palmer, Chair in Medical Oncology, Clatterbridge
More informationPancreatic cancer from the past to the future
Pancreatic cancer from the past to the future Darren Sigal, MD Scripps Clinic Pancreas and Bile Duct Cancer Group Division of Hematology/Oncology Scripps Clinic Pancreas and Bile Duct Cancer Group 1 Objectives
More informationNeoadjuvant therapy prior to surgical resection for previously explored pancreatic cancer patients is associated with improved survival
Original Article Neoadjuvant therapy prior to surgical resection for previously explored pancreatic cancer patients is associated with improved survival Fengchun Lu 1,2, Kevin C. Soares 1, Jin He 1, Ammar
More informationTreatment outcome of advanced pancreatic cancer patients who are ineligible for a clinical trial 臨床試験の適格基準を満たさない進行膵癌患者の治療成績. Akira Ueda, MD 植田亮
平成 28 年度学位論文 Treatment outcome of advanced pancreatic cancer patients who are ineligible for a clinical trial 臨床試験の適格基準を満たさない進行膵癌患者の治療成績 Akira Ueda, MD Department of Gastroenterology and Hematology, Faculty
More informationPancreatic Cancer. BIOLOGY: Not well defined (genetic and enviromental factors) CLINICAL PRESENTATION: Abd pain, jaundice, weight loss.
EloreMed Editor: Le Wang, MD, PhD Date of Update: 2/6/2018 UpToDate: Liposomal irinotecan (Onivyde) plus FU/LV is now approved for gemcitabine-refractory metastatic pancreatic cancer and recommended by
More informationA prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy
J Cancer Res Clin Oncol (2015) 141:1653 1660 DOI 10.1007/s00432-015-1953-y ORIGINAL ARTICLE CLINICAL ONCOLOGY A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationCetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS)
Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS) C Bokemeyer, E Staroslawska, A Makhson, I Bondarenko, JT Hartmann,
More informationP R O G R A M. 08:50 09:10 Present and future of surgery of pancreatic cancer: how far can we go?
P R O G R A M Course Day 1, Friday November 2, 2018 08:30 08:00 Official Opening Welcome Address 08:30 08:35 08:35 08:40 08:40 08:45 08:45 08:50 Jakob Izbicki (Germany), EFISDS President T. Seufferlein
More informationAdjuvant and neoadjuvant therapy for resectable pancreatic adenocarcinoma
Review Article on Pancreas Adenocarcinoma Page 1 of 8 Adjuvant and neoadjuvant therapy for resectable pancreatic adenocarcinoma Davendra P. S. Sohal Cleveland Clinic Taussig Cancer Institute, Cleveland,
More informationMulti-Institutional Experience with FOLFIRINOX in Pancreatic Adenocarcinoma
ORIGINAL ARTICLE Multi-Institutional Experience with FOLFIRINOX in Pancreatic Adenocarcinoma Parvin F Peddi 1, Sam Lubner 5, Robert McWilliams 6, Benjamin R Tan 1, Joel Picus 1, Steven M Sorscher 1, Rama
More informationDouglas B. Evans, MD 1, Ben George, MD 2, and Susan Tsai, MD, MHS 1
Ann Surg Oncol (2015) 22:3409 3413 DOI 10.1245/s10434-015-4649-2 EDITORIAL PANCREATIC TUMORS Non-metastatic Pancreatic Cancer: Resectable, Borderline Resectable, and Locally Advanced-Definitions of Increasing
More informationColon Cancer Liver Metastases: Liver-Directed Therapy
Colon Cancer Liver Metastases: Liver-Directed Therapy Shishir K. Maithel, MD FACS Assistant Professor of Surgery Division of Surgical Oncology Winship Cancer Institute Emory University August 10, 2014
More informationBMJ Open. A proposed model for prediction of survival based on a follow up study in unresectable pancreatic cancer
A proposed model for prediction of survival based on a follow up study in unresectable pancreatic cancer Journal: Manuscript ID: bmjopen-0-000 Article Type: Research Date Submitted by the Author: -Sep-0
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
of the clinical trial data for this outcome. Therefore, perc considered that the cost-effectiveness of cetuximab plus FOLFIRI would be at the higher end of the EGP s range of best estimates. Therefore,
More informationDecline of serum CA724 as a probable predictive factor for tumor response during chemotherapy of advanced gastric carcinoma
Original Article Decline of serum CA724 as a probable predictive factor for tumor response during chemotherapy of advanced gastric carcinoma Li Zou 1 *, Jun Qian 2 * 1 Department of Oncology, 2 Department
More informationPrognostic value of clinicopathological characteristics in patients with pancreatic cancer
Original Article rognostic value of clinicopathological characteristics in patients with pancreatic cancer Mei Geng 1, Haoping Xu 1, Ruobing Ren 1, Qing Qu 1, Chengfang Shangguan 1, Junwei Wu 1, Jinsong
More informationCorrelation of tumor size and survival in pancreatic cancer
Original Article (Management of Foregut Malignancies and Hepatobiliary Tract and Pancreas Malignancies) Correlation of tumor size and survival in pancreatic cancer Caitlin Takahashi 1, Ravi Shridhar 2,
More informationRESEARCH ARTICLE. Normalization of CA19-9 Following Resection for Pancreatic Ductal Adenocarcinoma is not Tantamount to being Cured?
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.2.661 Normalization of CA19-9 Following Resection for Pancreatic Ductal Adenocarcinoma is not Tantamount to being Cured? RESEARCH ARTICLE Normalization of CA19-9
More informationWhich Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy
Which Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy Joseph Chao, M.D. Assistant Clinical Professor Department of Medical Oncology & Therapeutics
More informationTechniques to Improve Resectability of Colorectal Liver Metastases Ching-Wei D. Tzeng, M.D.
Techniques to Improve Resectability of Colorectal Liver Metastases Ching-Wei D. Tzeng, M.D. Department of Surgery Grand Rounds University of Kentucky January 15, 2014 Metastatic Colorectal Cancer (CRC)
More informationDr Roopinder Gillmore July 2017
Dr Roopinder Gillmore July 2017 Resectable Borderline / locally advanced Metastatic 15-20% 15-20% 60-70% 22-28 months 9-15 months 6-12 months Does the patient have resectable disease?? Definitely not
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationAuthor s response to reviews
Author s response to reviews Title: Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT)) - Study protocol for a national, multicentre
More informationEffects of S-1 as a second-line chemotherapy for patients with relapsed pancreatic cancer
ONCOLOGY LETTERS 2: 1313-1317, 2011 Effects of S-1 as a second-line chemotherapy for patients with relapsed pancreatic cancer KEINOSUKE ISHIDO, YOSHIKAZU TOYOKI, DAISUKE KUDO, NORIHISA KIMURA, DAISUKE
More informationOverview. Author Summary: Abstract and Brief Discussion
Overview First Published Online October 1, 2014 DOI: 10.1634/theoncologist.2014-0223 Title: S-1 as Monotherapy or in Combination With Leucovorin as Second-Line Treatment in Gemcitabine-Refractory Advanced
More informationReview. A. Di Leo 1 *, M. Buyse 2 & H. Bleiberg 1. Introduction. Design and main results of the trials
Review Annals of Oncology 15: 545 549, 2004 DOI: 10.1093/annonc/mdh127 Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical
More informationEvolving Standards of Care for Resected Pancreatic Cancer
Evolving Standards of Care for Resected Pancreatic Cancer Benjamin A. Weinberg, MD, Philip A. Philip, MD, PhD, and Mohamed E. Salem, MD Dr Weinberg is the chief fellow and Dr Salem is an assistant professor
More informationPreoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages
Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages Sonja Gillen 1, Tibor Schuster 2, Christian Meyer zum Büschenfelde 3,
More informationOVERALL CLINICAL BENEFIT
cetuximab plus FOLFIRI to convert unresectable liver metastatses to resectable, perc confirmed that neither the FIRE-3 study nor the CRYSTAL study were designed to assess resectability and, in the absence
More informationDocetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.
Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled
More information